|
|||||
|
|
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor,in patients with advanced solid tumors |
|
| Authors: | Jordi Rodon Irene Braña Lillian L Siu Maja J De Jonge Natasha Homji David Mills Emmanuelle Di Tomaso Celine Sarr Lucia Trandafir Cristian Massacesi Ferry Eskens Johanna C Bendell |
| Affiliation: | 1. Vall d’Hebron University Hospital, Barcelona, Spain 11. Medical Oncology Department, Vall d’Hebrón University Hospital, Barcelona, Spain 2. Universitat Autònoma de Barcelona, Barcelona, Spain 3. Princess Margaret Cancer Centre, Toronto, Canada 4. Erasmus MC Cancer Institute, Rotterdam, The Netherlands 5. Novartis Pharmaceuticals, Florham Park, NJ, USA 6. Novartis Pharma AG, Basel, Switzerland 7. Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA 8. Novartis Pharmaceuticals, East Hanover, NJ, USA 9. Novartis Oncology, Paris, France 10. Sarah Cannon Research Institute, Nashville, TN, USA |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |